Our company has established connections with many research facilities across the country. We strive to constantly develop cutting-edge technologies and new services, so we are actively collaborating with many institutions to achieve mutually benefits.
Antibody-based drugs Research and Development (R&D)
KangTi with have entered in strategic cooperation with pharmaceutical companies to jointly develop a new generation of VHH antibody-based range of drugs. Our company have signed agreements with established bio-pharmaceutical companies in Beijing and Wuxi to jointly discover antibody-based drugs, collaborate with Immunochina Pharmaceuticals, Beijing to develop CAR-T drugs for cancer immunotherapy and Lanzhou University in the development of cervical cancer treatment
Antibody-based diagnostics R&D
KangTi with AlpaLife established cooperation with many diagnostic test and reagent manufacturers national
wide to jointly develop antibody-based
reagents for detection of arteriosclerosis, rheumatoid arthritis, acute
inflammation and infection, and Alzheimer's disease.